Literature DB >> 12115503

MSI in endometrial carcinoma: absence of MLH1 promoter methylation is associated with increased familial risk for cancers.

Alison J Whelan1, Sheri Babb, David G Mutch, Janet Rader, Thomas J Herzog, Christina Todd, Jennifer L Ivanovich, Paul J Goodfellow.   

Abstract

Loss of DNA mismatch repair occurs in a variety of malignancies and is associated with genome-wide instability of microsatellite repeats, a molecular phenotype referred to as microsatellite instability (MSI). MSI is a consistent feature of colorectal and endometrial tumors from patients with hereditary non-polyposis colorectal cancer (HNPCC). Sporadic colorectal and endometrial cancers that exhibit MSI frequently have methylation of the MLH1 promoter. We undertook a detailed family and medical history study to compare family cancer risk for women with MSI-positive and -negative endometrial cancers. The MLH1 promoter methylation status was determined for all cancers. Family histories were developed for 80 probands (40 with MSI-positive and 40 with MSI-negative tumors). The numbers of reported cancers in first- and second-degree relatives of the 2 groups were similar. There was a modest increase in familial cancer clustering for MSI-positive probands. When MSI-positive tumors were subclassified according to MLH1 promoter methylation, a clear association between methylation status and familial cancer risk was evident. Women with MSI-positive endometrial cancers in which the MLH1 promoter was unmethylated had a 7-fold relative risk (RR) of demonstrating familial clustering of cancers [RR 7.07 (95% confidence interval 2.29-21.81)]. The women with MSI-positive, MLH1-unmethylated tumors were significantly younger than the rest of the study population (56.1 years vs. 65.4, p < or = 0.01). Age of onset and tumor MSI not associated with MLH1 promoter methylation may point to women with a genetic susceptibility to malignancies. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12115503     DOI: 10.1002/ijc.10429

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  11 in total

1.  Clinicopathologic Significance of Mismatch Repair Defects in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study.

Authors:  D Scott McMeekin; David L Tritchler; David E Cohn; David G Mutch; Heather A Lankes; Melissa A Geller; Matthew A Powell; Floor J Backes; Lisa M Landrum; Richard Zaino; Russell D Broaddus; Nilsa Ramirez; Feng Gao; Shamshad Ali; Kathleen M Darcy; Michael L Pearl; Paul A DiSilvestro; Shashikant B Lele; Paul J Goodfellow
Journal:  J Clin Oncol       Date:  2016-06-20       Impact factor: 44.544

Review 2.  Importance of PCR-based Tumor Testing in the Evaluation of Lynch Syndrome-associated Endometrial Cancer.

Authors:  Amanda S Bruegl; Annessa Kernberg; Russell R Broaddus
Journal:  Adv Anat Pathol       Date:  2017-11       Impact factor: 3.875

3.  Utility of MLH1 methylation analysis in the clinical evaluation of Lynch Syndrome in women with endometrial cancer.

Authors:  Amanda S Bruegl; Bojana Djordjevic; Diana L Urbauer; Shannon N Westin; Pamela T Soliman; Karen H Lu; Rajyalakshmi Luthra; Russell R Broaddus
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

Review 4.  Genetic counseling considerations in the evaluation of families for Lynch syndrome--a review.

Authors:  Scott M Weissman; Cecelia Bellcross; Christina Chimera Bittner; Mary E Freivogel; Joy Larsen Haidle; Pardeep Kaurah; Anna Leininger; Selvi Palaniappan; Kelle Steenblock; Thuy M Vu; Molly S Daniels
Journal:  J Genet Couns       Date:  2010-10-08       Impact factor: 2.537

5.  Excess of early onset multiple myeloma in endometrial cancer probands and their relatives suggests common susceptibility.

Authors:  Israel Zighelboim; Sheri Babb; Feng Gao; Matthew A Powell; David G Mutch; Paul J Goodfellow
Journal:  Gynecol Oncol       Date:  2007-03-01       Impact factor: 5.482

6.  Prevalence of defective DNA mismatch repair and MSH6 mutation in an unselected series of endometrial cancers.

Authors:  Paul J Goodfellow; Barbara M Buttin; Thomas J Herzog; Janet S Rader; Randall K Gibb; Elizabeth Swisher; Katherine Look; Ken C Walls; Ming-Yu Fan; David G Mutch
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-05       Impact factor: 11.205

7.  Anthropometric measures and the risk of endometrial cancer, overall and by tumor microsatellite status and histological subtype.

Authors:  Ernest K Amankwah; Christine M Friedenreich; Anthony M Magliocco; Rollin Brant; Kerry S Courneya; Thomas Speidel; Wahida Rahman; Annie R Langley; Linda S Cook
Journal:  Am J Epidemiol       Date:  2013-05-14       Impact factor: 4.897

8.  Clustering of Lynch syndrome malignancies with no evidence for a role of DNA mismatch repair.

Authors:  Ashley S Case; Israel Zighelboim; David G Mutch; Sheri A Babb; Amy P Schmidt; Alison J Whelan; Stephen N Thibodeau; Paul J Goodfellow
Journal:  Gynecol Oncol       Date:  2007-11-26       Impact factor: 5.482

9.  Penetrance and expressivity of MSH6 germline mutations in seven kindreds not ascertained by family history.

Authors:  Barbara M Buttin; Matthew A Powell; David G Mutch; Sheri A Babb; Phyllis C Huettner; Tina Bocker Edmonston; Thomas J Herzog; Janet S Rader; Randall K Gibb; Alison J Whelan; Paul J Goodfellow
Journal:  Am J Hum Genet       Date:  2004-04-19       Impact factor: 11.025

10.  Intra-tumor heterogeneity of MLH1 promoter methylation revealed by deep single molecule bisulfite sequencing.

Authors:  Katherine E Varley; David G Mutch; Tina B Edmonston; Paul J Goodfellow; Robi D Mitra
Journal:  Nucleic Acids Res       Date:  2009-06-03       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.